9mqb: Difference between revisions
From Proteopedia
Jump to navigationJump to search
m Protected "9mqb" [edit=sysop:move=sysop] |
No edit summary |
||
| Line 1: | Line 1: | ||
The entry | ==Vitamin K-dependent gamma-carboxylase with Osteocalcin (mutant) and vitamin K hydroquinone and calcium== | ||
<StructureSection load='9mqb' size='340' side='right'caption='[[9mqb]], [[Resolution|resolution]] 3.37Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[9mqb]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=9MQB OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=9MQB FirstGlance]. <br> | |||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Electron Microscopy, [[Resolution|Resolution]] 3.37Å</td></tr> | |||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=6PL:(4S,7R)-4-HYDROXY-N,N,N-TRIMETHYL-9-OXO-7-[(PALMITOYLOXY)METHYL]-3,5,8-TRIOXA-4-PHOSPHAHEXACOSAN-1-AMINIUM+4-OXIDE'>6PL</scene>, <scene name='pdbligand=A1AVC:2-methyl-3-[(2E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-yl]naphthalene-1,4-diol'>A1AVC</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=9mqb FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=9mqb OCA], [https://pdbe.org/9mqb PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=9mqb RCSB], [https://www.ebi.ac.uk/pdbsum/9mqb PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=9mqb ProSAT]</span></td></tr> | |||
</table> | |||
== Disease == | |||
[https://www.uniprot.org/uniprot/VKGC_HUMAN VKGC_HUMAN] Pseudoxanthoma elasticum-like skin manifestations with retinitis pigmentosa;Hereditary combined deficiency of vitamin K-dependent clotting factors;Body skin hyperlaxity due to vitamin K-dependent coagulation factor deficiency. The disease is caused by variants affecting the gene represented in this entry. The disease is caused by variants affecting the gene represented in this entry. | |||
== Function == | |||
[https://www.uniprot.org/uniprot/VKGC_HUMAN VKGC_HUMAN] Mediates the vitamin K-dependent carboxylation of glutamate residues to calcium-binding gamma-carboxyglutamate (Gla) residues with the concomitant conversion of the reduced hydroquinone form of vitamin K to vitamin K epoxide (PubMed:17073445). Catalyzes gamma-carboxylation of various proteins, such as blood coagulation factors (F2, F7, F9 and F10), osteocalcin (BGLAP) or matrix Gla protein (MGP) (PubMed:17073445).<ref>PMID:17073445</ref> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
The gamma-carboxylation state of osteocalcin determines its essential functions in bone mineralization or systemic metabolism and serves as a prominent biomarker for bone health and vitamin K nutrition. This post-translational modification of glutamate residues is catalyzed by the membrane-embedded vitamin K-dependent gamma-carboxylase (VKGC), which typically recognizes protein substrates through their tightly bound propeptide that triggers gamma-carboxylation. However, the osteocalcin propeptide exhibits negligible affinity for VKGC. To understand the underlying molecular mechanism, we determined the cryo-electron microscopy structures of VKGC with osteocalcin carrying a native propeptide or a high-affinity variant at different carboxylation states. The structures reveal a large chamber in VKGC that maintains uncarboxylated and partially carboxylated osteocalcin in partially unfolded conformations, allowing their glutamate-rich region and C-terminal helices to engage with VKGC at multiple sites. Binding of this mature region together with the low-affinity propeptide effectively stimulates VKGC activity, similar to high-affinity propeptides that differ only in closely fitting interactions. However, the low-affinity propeptide renders osteocalcin prone to undercarboxylation at low vitamin K levels, thereby serving as a discernible biomarker. Overall, our studies reveal the unique interaction of osteocalcin with VKGC and provide a framework for designing therapeutic strategies targeting osteocalcin-related bone and metabolic disorders. | |||
Structural insights into the vitamin K-dependent gamma-carboxylation of osteocalcin.,Cao Q, Fan J, Ammerman A, Awasthi S, Lin Z, Mierxiati S, Chen H, Xu J, Garcia BA, Liu B, Li W Cell Res. 2025 Oct;35(10):735-749. doi: 10.1038/s41422-025-01161-0. Epub 2025 Sep , 2. PMID:40890294<ref>PMID:40890294</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
[[Category: | </div> | ||
[[Category: | <div class="pdbe-citations 9mqb" style="background-color:#fffaf0;"></div> | ||
[[Category: Cao | == References == | ||
[[Category: Liu | <references/> | ||
__TOC__ | |||
</StructureSection> | |||
[[Category: Homo sapiens]] | |||
[[Category: Large Structures]] | |||
[[Category: Cao Q]] | |||
[[Category: Li W]] | |||
[[Category: Liu B]] | |||
Latest revision as of 07:28, 8 October 2025
Vitamin K-dependent gamma-carboxylase with Osteocalcin (mutant) and vitamin K hydroquinone and calcium
| ||||||||||||